ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in New York, NY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Triple Negative Breast Cancer

Non-Small-Cell Lung Cancer trials near New York, NY, USA:

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

body radiation (SBRT) is a more effective treatment for early-stage non-small cell lung cancer (NSCLC) t...

Enrolling
Non-small Cell Lung Cancer Stage II
Non-small Cell Lung Cancer Stage IIIA
Radiation: Stereotactic Body Radiation Therapy
Drug: Durvalumab

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

New York, New York, United States and 8 other locations

Study of MGY825 single agent in adult patients with advanced non-small cell lung cancer....

Enrolling
Non-small Cell Lung Cancer
Drug: MGY825

Phase 1

Novartis
Novartis

New York, New York, United States and 12 other locations

This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: DS-1062a

Phase 2

Daiichi Sankyo
Daiichi Sankyo

New York, New York, United States and 83 other locations

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

New York, New York, United States and 48 other locations

3-DXd will be evaluated in participants with metastatic or unresectable NSCLC with EGFR activating mutation or squamous or non-squamous NSCL...

Enrolling
Non-Small Cell Lung Cancer (NSCLC)
Drug: HER3-DXd (FL-DP)
Drug: HER3-DXd (CTM-3 Lyo-DP)

Phase 1

Daiichi Sankyo
Daiichi Sankyo

New York, New York, United States and 35 other locations

with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non- ...

Active, not recruiting
Squamous Non Small Cell Lung Cancer
Nonsquamous Non Small Cell Lung Cancer
Drug: Etrumadenant
Drug: Zimberelimab

Phase 2

Arcus Biosciences
Arcus Biosciences

Lake Success, New York, United States and 46 other locations

type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Sunvozertinib

Phase 1, Phase 2

Dizal Pharma

New York, New York, United States and 123 other locations

with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) wi...

Enrolling
Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Drug: pemetrexed
Drug: LBL-007

Phase 2

BeiGene
BeiGene

New York, New York, United States and 60 other locations

in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with o...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Bronx, New York, United States and 209 other locations

Based on promising data from our laboratory demonstrating synergy between ablative local radiotherapy and FLT3 ligand immunotherapy in murine NSCLC m...

Active, not recruiting
Non-small Cell Lung Cancer (NSCLC)
Radiation: Stereotactic Body Radiotherapy (SBRT)
Drug: FLT3 Ligand Therapy (CDX-301)

Phase 2

Albert Einstein College of Medicine
Albert Einstein College of Medicine

Bronx, New York, United States

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems